Diligence memo · auto-generated · as of July 2, 2026
Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Orexigen Therapeutics, Inc. operates in Pharmaceuticals, based in LA JOLLA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Orexigen Therapeutics, Inc. has raised $275M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $165M on 2016-03-21.
Most recent recorded round closed around 2017-02-23.
Valuation (modeled)modeled
Provath models Orexigen Therapeutics, Inc. at approximately $1.8B (range $236M–$3.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.40× the median modeled value of Series D+ Pharmaceuticals companies in 2016–2018 (11 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 9.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 98% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Concordia International Corp., Surterra Holdings, Inc./DE, Ironwood Pharmaceuticals Inc, Melinta Therapeutics, Inc. /New/, Beam Therapeutics Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.